Galapagos to buy CellPoint, AboundBio to boost access to cell therapies
AboundBio will receive $14m from Galapagos under the agreed transaction.

AboundBio will receive $14m from Galapagos under the agreed transaction.
Oxurion has announced that clinical trials for THR-687, its novel pharmacotherapy for diabetic macular oedema, will not continue.
ByUCB and Microsoft have entered into a new multi-year, strategic collaboration.
Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and…
Belgian biopharmaceutical firm UCB has acquired US-based pharmaceutical company Engage Therapeutics for a cash consideration of $125m.
Life sciences firm Orionis Biosciences has partnered with Novartis to discover and design new drugs for the treatment of a…
Galapagos has expanded its research collaboration with Candian firm Fibrocor Therapeutics, which develops tissue-specific therapeutics for fibrotic diseases.
Cell-based drugs developer Promethera Biosciences has closed a Series D financing round to support its expansion in Asian markets, along…
Thank you for subscribing to Pharmaceutical Technology